| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Neisseria meningitidis modified through homologous recombination with an erythromycin antibiotic resistance cassette sequence to delete the rmp gene (NVRmp- 05/33) (GMC07002)
Record information and status
Record ID
46015
Status
Published
Date of creation
2008-07-24 16:04 UTC (mia.crager@cbd.int)
Date of last update
2008-07-24 16:04 UTC (bch@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Neisseria meningitidis modified through homologous recombination with an erythromycin antibiotic resistance cassette sequence to delete the rmp gene (NVRmp- 05/33) (GMC07002)
Developer(s)
Dr. Diana Martin
Principal Scientist
Institute of Environmental Science & Research (ESR)
34 Kenepuru Drive
Porirua
New Zealand
Phone:+64 04 914-0778
Fax:+64 04 914-0770
Email:diana.martin@esr.cri.nz
Url:ESR
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Neisseria meningitidis
Characteristics of the transformation process
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
Erythromycin Ribosomal Methylase A - Streptococcus pneumoniae
Resistance to antibiotics
Erythromycin Ribosomal Methylase B - Streptococcus pneumoniae
Resistance to antibiotics
Notes regarding the genetic elements introduced or modified in this LMO
The strain NVRmp 05/33 is a mutant of NZ05/33. It has only been modified in the rmp gene which has been truncated and replaced with an erythromycin antibiotic cassette prepared by transforming the parent strain NZ05/33 strain with an appropriate plasmid pBsΔrmpERM. The knockout mutant consists of the upstream and downstream homologous flanking regions of the rmp gene with the erythromycin antibiotic cassette sequence inserted in between these regions ie the gene that encodes the protein determining erythromycin resistance [4]. The result is a bacterium where most of the rmp gene has been deleted. This mutant is named NVRmp- 05/33 and has been made at the Novartis Vaccines, Siena, Italy.
LMO characteristics
Modified traits
  • Resistance to antibiotics
Additional Information
Additional Information
LMO intended for research purposes to determine if Rmp expression can reduce the effectiveness of the MeNZB vaccine.
Other relevant website address or attached documents

   
   
Rate this page  - 34 people have rated this page  
United Nations Environment Programme United Nations